# A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients

> **NCT07573332** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 5 (estimated)

## Conditions studied

- AQP4+ NMOSD

## Interventions

- **BIOLOGICAL:** CC-97540 (BMS-986353)
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT07573332
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2030-08-01
- **Final completion:** 2031-08-01
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07573332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07573332, "A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07573332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*